• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾脏病和冠状动脉疾病患者中肝纤维化标志物与死亡率结局的关联:来自1999 - 2018年美国国家健康与营养检查调查(NHANES)数据的见解

Association of Liver Fibrosis Markers with Mortality Outcomes in Patients with Chronic Kidney Disease and Coronary Artery Disease: Insights from the NHANES 1999-2018 Data.

作者信息

Ye Zixiang, Xie Enmin, Guo Ziyu, Gao Yanxiang, Han Zhongwei, Dou Kefei, Zheng Jingang

机构信息

Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Department of Cardiology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.

出版信息

Cardiorenal Med. 2025;15(1):153-163. doi: 10.1159/000543500. Epub 2025 Jan 21.

DOI:10.1159/000543500
PMID:39837280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11844702/
Abstract

INTRODUCTION

The objective of this research was to explore the possible link between markers of liver fibrosis and survival rates in a group of adults who have been diagnosed with both chronic kidney disease (CKD) and coronary artery disease (CAD).

METHODS

The National Health and Nutrition Examination Survey (NHANES) data (1999-2018) for participants with both CAD and CKD were analyzed. The fibrosis-4 index (FIB-4), Nonalcoholic Fatty Liver Score (NFS), Forns index, and aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio were identified as crucial biomarkers. All-cause and cardiovascular disease (CVD) mortality were primary outcomes, assessed using Cox models, Kaplan-Meier curves, and receiver operating characteristic (ROC) analysis.

RESULTS

A total of 1,192 CKD and CAD patients were included. The Cox regression analysis revealed substantial correlations between elevated FIB-4, NFS, Forns index, and AST/ALT levels and a heightened risk of all-cause (hazard ratio [HR]: 1.188, 95% confidence interval [CI]: 1.108-1.274; HR: 1.145, 95% CI: 1.069-1.227; HR: 1.142, 95% CI: 1.081-1.201; HR: 1.316, 95% CI: 1.056-1.639, respectively) and CVD mortality (HR: 1.133, 95% CI: 1.007-1.275; HR: 1.155, 95% CI: 1.024-1.303; HR: 1.208, 95% CI: 1.109-1.316 and HR: 1.636, 95% CI: 1.203-2.224, respectively). The ROC analysis indicated comparable predictive accuracy for all three biomarkers, with AST/ALT showing slightly superior performance.

CONCLUSION

Liver fibrosis markers, including AST/ALT, NFS, Forns index and FIB-4, are significant mortality predictors in CAD-CKD patients. The AST/ALT ratio, being easily measurable, may serve as an effective predictive tool for risk stratification in this population.

摘要

引言

本研究的目的是探讨一组同时被诊断患有慢性肾脏病(CKD)和冠状动脉疾病(CAD)的成年人中,肝纤维化标志物与生存率之间的可能联系。

方法

分析了患有CAD和CKD的参与者的美国国家健康与营养检查调查(NHANES)数据(1999 - 2018年)。纤维化-4指数(FIB-4)、非酒精性脂肪肝评分(NFS)、福恩斯指数以及天冬氨酸转氨酶/丙氨酸转氨酶(AST/ALT)比值被确定为关键生物标志物。全因死亡率和心血管疾病(CVD)死亡率是主要结局,使用Cox模型、Kaplan-Meier曲线和受试者工作特征(ROC)分析进行评估。

结果

共纳入1192例CKD和CAD患者。Cox回归分析显示,FIB-4、NFS、福恩斯指数升高以及AST/ALT水平升高与全因死亡风险增加(风险比[HR]:1.188,95%置信区间[CI]:1.108 - 1.274;HR:1.145,95% CI:1.069 - 1.227;HR:1.142,95% CI:1.081 - 1.201;HR:1.316,95% CI:1.056 - 1.639,分别)和CVD死亡风险增加(HR:1.133,95% CI:1.007 - 1.275;HR:1.155,95% CI:1.024 - 1.303;HR:1.208,95% CI:1.109 - 1.316;HR:1.636,95% CI:1.203 - 2.224,分别)之间存在显著相关性。ROC分析表明,这三种生物标志物的预测准确性相当,其中AST/ALT表现略优。

结论

包括AST/ALT、NFS、福恩斯指数和FIB-4在内的肝纤维化标志物是CAD-CKD患者死亡率的重要预测指标。AST/ALT比值易于测量,可作为该人群风险分层的有效预测工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96a8/11844702/238755cd99a9/crm-2025-0015-0001-543500_F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96a8/11844702/acc0f9b13ac2/crm-2025-0015-0001-543500_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96a8/11844702/f6dc6f91ebc1/crm-2025-0015-0001-543500_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96a8/11844702/238755cd99a9/crm-2025-0015-0001-543500_F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96a8/11844702/acc0f9b13ac2/crm-2025-0015-0001-543500_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96a8/11844702/f6dc6f91ebc1/crm-2025-0015-0001-543500_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96a8/11844702/238755cd99a9/crm-2025-0015-0001-543500_F03.jpg

相似文献

1
Association of Liver Fibrosis Markers with Mortality Outcomes in Patients with Chronic Kidney Disease and Coronary Artery Disease: Insights from the NHANES 1999-2018 Data.慢性肾脏病和冠状动脉疾病患者中肝纤维化标志物与死亡率结局的关联:来自1999 - 2018年美国国家健康与营养检查调查(NHANES)数据的见解
Cardiorenal Med. 2025;15(1):153-163. doi: 10.1159/000543500. Epub 2025 Jan 21.
2
Elevated ALT/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States.ALT/AST 比值升高作为非酒精性脂肪性肝病风险和严重程度的标志物:来自美国横断面分析的见解。
Front Endocrinol (Lausanne). 2024 Aug 26;15:1457598. doi: 10.3389/fendo.2024.1457598. eCollection 2024.
3
Association of liver fibrosis scores with all-cause and cardiovascular mortality in patients with heart failure.心力衰竭患者肝纤维化评分与全因死亡率和心血管死亡率的关联
Clin Transl Sci. 2024 Dec;17(12):e70104. doi: 10.1111/cts.70104.
4
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.在退伍军人健康管理局中识别非酒精性脂肪性肝病的肝纤维化程度。
Dig Dis Sci. 2018 Sep;63(9):2259-2266. doi: 10.1007/s10620-018-5123-3. Epub 2018 May 19.
5
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.肥胖和丙氨酸氨基转移酶水平对非酒精性脂肪性肝病患者无创性工具诊断晚期肝纤维化的准确性的影响。
Am J Gastroenterol. 2019 Jun;114(6):916-928. doi: 10.14309/ajg.0000000000000153.
6
Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病的非侵入性纤维化评分系统在非裔美国人和白人患者中的准确性。
Clin Transl Gastroenterol. 2020 Apr;11(4):e00165. doi: 10.14309/ctg.0000000000000165.
7
Liver fibrosis stage based on the four factors (FIB-4) score or Forns index in adults with chronic hepatitis C.基于四项因素(FIB-4)评分或 Forns 指数的成人慢性丙型肝炎肝纤维化分期。
Cochrane Database Syst Rev. 2024 Aug 13;8(8):CD011929. doi: 10.1002/14651858.CD011929.pub2.
8
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.年龄作为晚期非酒精性脂肪性肝病纤维化准确无创诊断的混杂因素。
Am J Gastroenterol. 2017 May;112(5):740-751. doi: 10.1038/ajg.2016.453. Epub 2016 Oct 11.
9
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.美国非酒精性脂肪性肝病成人患者中无创性纤维化标志物与死亡率之间的关系。
Hepatology. 2013 Apr;57(4):1357-65. doi: 10.1002/hep.26156. Epub 2013 Jan 25.
10
Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.美国非酒精性脂肪肝成人中的非侵入性纤维化标志物与慢性肾脏病
Eur J Gastroenterol Hepatol. 2018 Apr;30(4):404-410. doi: 10.1097/MEG.0000000000001045.

引用本文的文献

1
Correlation between hs-CRP-triglyceride glucose index and NAFLD and liver fibrosis.高敏C反应蛋白-甘油三酯葡萄糖指数与非酒精性脂肪性肝病及肝纤维化的相关性
BMC Gastroenterol. 2025 Apr 12;25(1):252. doi: 10.1186/s12876-025-03870-7.

本文引用的文献

1
Difference in hematocrit and plasma albumin levels as an early biomarker of severity and prognosis in patients with severe fever and thrombocytopenia syndrome.血细胞比容和血浆白蛋白水平的差异作为严重发热伴血小板减少综合征患者严重程度和预后的早期生物标志物。
J Med Virol. 2024 Oct;96(10):e29941. doi: 10.1002/jmv.29941.
2
Paeoniflorin protects hepatocytes from APAP-induced damage through launching autophagy via the MAPK/mTOR signaling pathway.芍药苷通过 MAPK/mTOR 信号通路启动自噬来保护肝细胞免受 APAP 诱导的损伤。
Cell Mol Biol Lett. 2024 Sep 7;29(1):119. doi: 10.1186/s11658-024-00631-4.
3
Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics.
肝脏健康和脂肪变性的基因组位点发现揭示了与谷胱甘肽氧化还原遗传学的重叠。
Redox Biol. 2024 Sep;75:103248. doi: 10.1016/j.redox.2024.103248. Epub 2024 Jun 19.
4
Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study.非酒精性脂肪性肝病与 2 型糖尿病患者心血管疾病及全因死亡的相关性:全国范围内基于人群的研究。
BMJ. 2024 Feb 13;384:e076388. doi: 10.1136/bmj-2023-076388.
5
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.代谢相关脂肪性肝病与心血管疾病风险。
Gut. 2024 Feb 23;73(3):533-540. doi: 10.1136/gutjnl-2023-331003.
6
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association.心血管-肾脏-代谢(CKM)综合征的科学证据和临床管理概要:美国心脏协会的科学声明
Circulation. 2023 Nov 14;148(20):1636-1664. doi: 10.1161/CIR.0000000000001186. Epub 2023 Oct 9.
7
Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease.肝纤维化评分与冠状动脉疾病:代谢功能障碍相关脂肪性肝病患者的新发现
Diabetes Metab Syndr Obes. 2023 Aug 29;16:2627-2637. doi: 10.2147/DMSO.S426102. eCollection 2023.
8
Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.纤维化 4 指数评分可预测脂肪性肝病各谱中并存的冠状动脉疾病。
Dig Dis Sci. 2023 Sep;68(9):3765-3773. doi: 10.1007/s10620-023-07987-1. Epub 2023 Jul 1.
9
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.非酒精性脂肪性肝病患者临床结局预测的无创性检查和组织学检查的效能:一项个体参与者数据荟萃分析。
Lancet Gastroenterol Hepatol. 2023 Aug;8(8):704-713. doi: 10.1016/S2468-1253(23)00141-3. Epub 2023 Jun 5.
10
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.应用 ELF 试验、FIB-4 和 NAFLD 纤维化评分对人群进行肝病筛查。
J Hepatol. 2023 Aug;79(2):277-286. doi: 10.1016/j.jhep.2023.04.002. Epub 2023 Apr 21.